Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS) (2023)
https://pubmed.ncbi.nlm.nih.gov/38114199/

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study (2022)
https://pubmed.ncbi.nlm.nih.gov/34244706/

Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/34270707/

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database (2022)
https://pubmed.ncbi.nlm.nih.gov/35319735/

Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS) (2022)
https://pubmed.ncbi.nlm.nih.gov/36597983/

Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database (2021)
https://pubmed.ncbi.nlm.nih.gov/32911531/